Burjeel to locally manufacture CAR-T cell therapies in new partnership | Healthcare Asia Magazine
, Middle East
Photo from Burjeel Holdings via LinkedIn

Burjeel to locally manufacture CAR-T cell therapies in new partnership

The initiative aims to offer therapies at costs up to 90% lower.

Burjeel Holdings has partnered with US-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs.

The non-profit will provide the group with technology, materials, training, and lentiviral vectors to support local manufacturing and clinical development.

The programme’s first phase will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!